Mylan 'strongly requests' to see shareholder report and defends Robert Coury record

7 June 2017

Mylan (Nasdaq: MYL) is fighting battles on multiple fronts, including over price increases of its EpiPen (epinephrine) devices and as it races to market with its biosimilar products.

But the Netherlands-incorporated drugmaker is facing another fight nearer to home – with its own shareholders, who are seeking to block its 2017 payment plans and in particular want the board’s chairman Robert Coury voted out.

"Mr Coury has been the key architect in taking Mylan from a small domestic company 15 years ago to a global leader"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK